Inosine Pranobex: meta-analysis of COVID-19 studies

All studies   Mortality   Recovery   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 29% 2 414 Improvement, Studies, Patients Relative Risk Mortality 46% 1 - RCTs 27% 1 414 Early 29% 2 414 Inosine Pranobex for COVID-19 c19early.org April 2026 Favorsinosine pranobex Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jayanthi (DB RCT) 27% 0.73 [0.59-0.90] no recov. 79/204 112/210 Improvement, RR [CI] Treatment Control Veselý 46% 0.54 [0.25-1.16] death population-based cohort Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0012 Early treatment 29% 0.71 [0.58-0.87] 79/204 112/210 29% lower risk All studies 29% 0.71 [0.58-0.87] 79/204 112/210 29% lower risk 2 inosine pranobex COVID-19 studies c19early.org April 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0012 Effect extraction pre-specified(most serious outcome) Favors inosine pranobex Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Veselý 46% 0.54 [0.25-1.16] population-based cohort Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Early treatment 46% 0.54 [0.25-1.16] 46% lower risk All studies 46% 0.54 [0.25-1.16] 46% lower risk 1 inosine pranobex COVID-19 mortality result c19early.org April 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Favors inosine pranobex Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jayanthi (DB RCT) 27% 0.73 [0.59-0.90] no recov. 79/204 112/210 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0034 Early treatment 27% 0.73 [0.59-0.90] 79/204 112/210 27% lower risk All studies 27% 0.73 [0.59-0.90] 79/204 112/210 27% lower risk 1 inosine pranobex COVID-19 recovery result c19early.org April 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0034 Favors inosine pranobex Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jayanthi (DB RCT) 27% 0.73 [0.59-0.90] no recov. 79/204 112/210 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0034 Early treatment 27% 0.73 [0.59-0.90] 79/204 112/210 27% lower risk All studies 27% 0.73 [0.59-0.90] 79/204 112/210 27% lower risk 1 inosine pranobex COVID-19 Randomized Controlled Trial c19early.org April 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0034 Effect extraction pre-specified(most serious outcome) Favors inosine pranobex Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jayanthi (DB RCT) 27% 0.73 [0.59-0.90] no recov. 79/204 112/210 Improvement, RR [CI] Treatment Control Veselý 46% 0.54 [0.25-1.16] death population-based cohort Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0012 Early treatment 29% 0.71 [0.58-0.87] 79/204 112/210 29% lower risk All studies 29% 0.71 [0.58-0.87] 79/204 112/210 29% lower risk 2 inosine pranobex COVID-19 peer reviewed studies c19early.org April 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0012 Effect extraction pre-specified(most serious outcome) Favors inosine pranobex Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jayanthi (DB RCT) 27% 0.73 [0.59-0.90] no recov. 79/204 112/210 Improvement, RR [CI] Treatment Control Jayanthi (DB RCT) 6% 0.94 [0.41-2.16] no recov. 10/204 11/210 Jayanthi (DB RCT) 33% 0.67 [0.54-0.84] no improv. 72/204 110/210 Jayanthi (DB RCT) -14% 1.14 [0.47-2.76] no improv. 10/204 9/210 Veselý 46% 0.54 [0.25-1.16] death population-based cohort Veselý 22% 0.78 [0.71-0.85] death population-based cohort Veselý 65% 0.35 [0.24-0.51] death Inosine pranobex COVID-19 outcomes c19early.org April 2026 Favors inosine pranobex Favors control